Payment overview · 2025
General Payments
$1,167.84
64 reported records · 20 companies
Healthcare provider profile · identity verified
Saad Amin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHEBORO, NC · NPI 1720046147
Verified facts
What the public records show
CMS Open Payments records show Saad Amin, MD received $1,167.84 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.23 | 13.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.18 | 12.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.96 | 11.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.88 | 10.0% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $104.45 | 8.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.08 | 6.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.63 | 5.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.79 | 5.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.40 | 4.7% | 3 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $45.36 | 3.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.14 | 2.3% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $25.19 | 2.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.05 | 2.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.09 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.14 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.95 | 1.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.54 | 1.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.89 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.45 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,167.84 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.96 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.61 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.54 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.88 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.72 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.50 | 4 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $90.87 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $86.93 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.39 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.63 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.59 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.40 | 3 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $31.34 | 2 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 259 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
259 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 482 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 76 |
| Gabapentin | Gabapentin | 349 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 69 |
| Furosemide | Furosemide | 271 | 68 |
| Omeprazole | Omeprazole | 262 | 63 |
| Eliquis | Apixaban | 259 | 49 |
| Losartan Potassium | Losartan Potassium | 241 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 61 |
| Metformin Hcl Er | Metformin Hcl | 215 | 47 |
| Potassium Chloride | Potassium Chloride | 203 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 46 |
| Sertraline Hcl | Sertraline Hcl | 193 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 47 |
| Tramadol Hcl | Tramadol Hcl | 157 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 33 |
| Metformin Hcl | Metformin Hcl | 147 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 44 |
| Carvedilol | Carvedilol | 139 | 33 |
| Trazodone Hcl | Trazodone Hcl | 135 | 32 |
| Mirtazapine | Mirtazapine | 132 | 37 |
| Meloxicam | Meloxicam | 128 | 31 |
| Montelukast Sodium | Montelukast Sodium | 125 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 35 |
| Lisinopril | Lisinopril | 124 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 29 |
| Jardiance | Empagliflozin | 123 | 21 |
| Allopurinol | Allopurinol | 121 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 47 |
| Ozempic | Semaglutide | 107 | 22 |
| Glimepiride | Glimepiride | 104 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 23 |
| Farxiga | Dapagliflozin Propanediol | 102 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 16 |
| Donepezil Hcl | Donepezil Hcl | 89 | 27 |
| Pregabalin | Pregabalin | 89 | 22 |
| Memantine Hcl | Memantine Hcl | 88 | 21 |
| Ezetimibe | Ezetimibe | 82 | 15 |
| Trulicity | Dulaglutide | 82 | 14 |
| Linzess | Linaclotide | 79 | 15 |
| Famotidine | Famotidine | 77 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 13 |
| Alprazolam | Alprazolam | 71 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 19 |
| Simvastatin | Simvastatin | 69 | 18 |
| Spironolactone | Spironolactone | 65 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | 11 |
| Cephalexin | Cephalexin | 64 | 48 |
| Finasteride | Finasteride | 64 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Celecoxib | Celecoxib | 62 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 16 |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Latanoprost | Latanoprost | 58 | 13 |
| Repatha Sureclick | Evolocumab | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 12 |
| Xarelto | Rivaroxaban | 55 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 11 |
| Atenolol | Atenolol | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 24 |
| Divalproex Sodium | Divalproex Sodium | 43 | 11 |
| Lorazepam | Lorazepam | 43 | 15 |
| Methocarbamol | Methocarbamol | 43 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Colchicine | Colchicine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Torsemide | Torsemide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 14 |
| Valsartan | Valsartan | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,167.84 · 64 records | Novo Nordisk Inc | ARISTADA, BREZTRI, CAPLYTA, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GIAPREZA, IBSRELA, Kerendia, LEQEMBI, LEQVIO, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, WINREVAIR, Wegovy, ZAVZPRET, ZEPBOUND, ZERBAXA, Zemaira | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error